Commentary on management of osteoporosis in advanced CKD - common view of a nephrologist and a bone specialist

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F19%3AN0000175" target="_blank" >RIV/00064173:_____/19:N0000175 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.4158/EP-2018-0311" target="_blank" >https://doi.org/10.4158/EP-2018-0311</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Commentary on management of osteoporosis in advanced CKD - common view of a nephrologist and a bone specialist

Popis výsledku v původním jazyce

The manuscript summarizes current consensual view of bone specialists and a nephrologist of the management of osteoporosis in patients with advanced chronic kidney disease (CKD) as a part of CKD-MBD (mineral and bone disorder associated with CKD). Osteoporosis has been recently accepted as a subunit of CKD-MBD, occurring in up to one third of advanced CKD patients, with fractures being the most severe complication. Diagnosis and differential diagnosis is currently based on non-invasive procedures (densitometry, laboratory assessment of calcium-phosphate metabolism and bone turnover); originally recommended bone biopsy is reserved for unclear cases. Specific treatment is complicated since majority of anti-osteoporotic drugs are contraindicated in advanced CKD and all of them lack robust data on effectiveness and safety in this specific population.

Název v anglickém jazyce

Commentary on management of osteoporosis in advanced CKD - common view of a nephrologist and a bone specialist

Popis výsledku anglicky

The manuscript summarizes current consensual view of bone specialists and a nephrologist of the management of osteoporosis in patients with advanced chronic kidney disease (CKD) as a part of CKD-MBD (mineral and bone disorder associated with CKD). Osteoporosis has been recently accepted as a subunit of CKD-MBD, occurring in up to one third of advanced CKD patients, with fractures being the most severe complication. Diagnosis and differential diagnosis is currently based on non-invasive procedures (densitometry, laboratory assessment of calcium-phosphate metabolism and bone turnover); originally recommended bone biopsy is reserved for unclear cases. Specific treatment is complicated since majority of anti-osteoporotic drugs are contraindicated in advanced CKD and all of them lack robust data on effectiveness and safety in this specific population.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů